Bristol-Myers Squibb Company

NYSE: BMY
$55.83
-$0.98 (-1.7%)
Closing Price on January 10, 2025

BMY Articles

The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has increased.
The short interest data have been released for the August 31 settlement date, and for the selected pharmaceutical stocks, short interest is mixed.
The August 14 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. ThinkstockWith a very nervous market, and the end of...
Bristol-Myers Squibb announced that the FDA has now extended the action date for the supplemental biologics license application for Opdivo in the war against advanced melanoma.
The short interest data have been released for the July 31 settlement date, and for most of the selected pharmaceutical stocks, short interest decreased.
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of August and added some color.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. ThinkstockThe short interest data have been released for...
Bristol-Myers Squibb released better-than-expected second-quarter financial results before the markets opened Thursday.
The June 30 short interest data have been compared with the previous figures, and across the selected pharmaceutical stocks, short interest decreased.
How much are big pharmaceutical companies really spending to get their drugs out there in the public eye?
The June 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
The May 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest is down.
Credit Suisse has updated its autoimmune market model and it sees implications for all of the large cap U.S. pharmaceutical companies in its coverage.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. ThinkstockThe American Society of Clinical Oncology’s...
AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.